nach oben

Breast Cancer Research and Treatment

Erschienen in:

13.02.2020 | Epidemiology

Trends of female and male breast cancer incidence at the global, regional, and national levels, 1990–2017

verfasst von: Zhilin Chen, Lu Xu, Wenjie Shi, Fanyu Zeng, Rui Zhuo, Xinbao Hao, Pingming Fan

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Breast cancer is a major public health concern worldwide and shows significant heterogeneity between male and female. Knowing the global incidence landscape in both sexes is critical for the breast cancer prevention and the reduction in disease burden.

Methods

We retrieved the incidence data of breast cancer in both sexes from the Global Burden of Disease 2017 database. Average annual percentage change was used to quantify the temporal trends of breast cancer incidence.

Results

Between 1990 and 2017, the number of newly diagnosed female breast cancer (FBC) cases increased from 870.2 thousand to 1937.6 thousand, with the age-standardized incidence rate (ASR) significantly increased from 39.2/100,000 to 45.9/100,000. A total of 166 countries experienced a significant increase in FBC-ASR. The most pronounced increase was mainly found in developing countries. The decrease was mostly detected in several developed countries, such as the USA and the UK. Male breast cancer (MBC) is a rare carcinoma and has no evident cluster across the world. Worldwide, the number of newly diagnosed MBC cases increased from 8.5 thousand in 1990 to 23.1 thousand in 2017, with the ASR significantly increased from 0.46/100,000 to 0.61/100,000. A total of 123 countries showed a significant increasing trend in MBC-ASR.

Conclusions

Breast cancer incidence rates are increasing in most countries in both sexes, although the epidemiological features were not completely shared between FBC and MBC. More emphases should be placed on breast cancer primary prevention and the prevention strategies might need to be tailored for both FBC and MBC.

Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424PubMed

Fitzmaurice C, Abate D, Abbasi N et al (2019) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2019.2996 CrossRefPubMedPubMedCentral

Abubakar M, Sung H, Bcr D et al (2018) Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: analysis of 3012 women from an indigenous Asian population. Breast Cancer Res 20(1):114CrossRefPubMedPubMedCentral

Engmann NJ, Golmakani MK, Miglioretti DL et al (2017) Population-attributable risk proportion of clinical risk factors for breast cancer. JAMA Oncol 3(9):1228–1236CrossRefPubMedPubMedCentral

Pfeiffer RM, Webb-Vargas Y, Wheeler W, Gail MH (2018) Proportion of U.S. trends in breast cancer incidence attributable to long-term changes in risk factor distributions. Cancer Epidemiol Biomarkers Prev 27(10):1214–1222CrossRefPubMedPubMedCentral

Kuchenbaecker KB, Hopper JL, Barnes DR et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416CrossRefPubMed

Michailidou K, Lindstrom S, Dennis J et al (2017) Association analysis identifies 65 new breast cancer risk loci. Nature 551(7678):92–94CrossRefPubMedPubMedCentral

Sung H, Siegel RL, Torre LA et al (2019) Global patterns in excess body weight and the associated cancer burden. CA Cancer J Clin 69(2):88–112PubMed

Liu N, Johnson KJ, Ma CX (2018) Male breast cancer: an updated surveillance, epidemiology, and end results data analysis. Clin Breast Cancer 18(5):e997–e1002CrossRefPubMed

10.

Korde LA, Zujewski JA, Kamin L et al (2010) Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 28(12):2114–2122CrossRefPubMedPubMedCentral

11.

Gucalp A, Traina TA, Eisner JR et al (2019) Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treat 173(1):37–48CrossRefPubMed

12.

Wang F, Shu X, Meszoely I et al (2019) Overall mortality after diagnosis of breast cancer in men vs women. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2019.2803 CrossRefPubMedPubMedCentral

13.

GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392(10159):1789–1858CrossRef

14.

Liu Z, Jiang Y, Yuan H et al (2019) The trends in incidence of primary liver cancer caused by specific etiologies: results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. J Hepatol 70(4):674–683CrossRefPubMed

15.

Lin L, Yan L, Liu Y et al (2019) Incidence and death in 29 cancer groups in 2017 and trend analysis from 1990 to 2017 from the Global Burden of Disease Study. J Hematol Oncol 12(1):96CrossRefPubMedPubMedCentral

16.

Global Burden of Disease Collaborative Network (2018) Global Burden of Disease Study 2017 (GBD 2017) Results. Institute for Health Metrics and Evaluation (IHME), Seattl. https://ghdx.healthdata.org/gbd-results-tool.

17.

GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388(10053):1545–1602CrossRef

18.

GBD 2016 Causes of Death Collaborators (2017) Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390(10100):1151–1210CrossRef

19.

GBD 2017 Causes of Death Collaborators (2018) Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392(10159):1736–1788CrossRef

20.

Allemani C, Matsuda T, Di Carlo V et al (2018) Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391(10125):1023–1075CrossRefPubMedPubMedCentral

21.

DeSantis CE, Bray F, Ferlay J et al (2015) International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev 24(10):1495–1506CrossRefPubMed

22.

Youlden DR, Cramb SM, Dunn NA et al (2012) The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol 36(3):237–248CrossRefPubMed

23.

Loberg M, Lousdal ML, Bretthauer M, Kalager M (2015) Benefits and harms of mammography screening. Breast Cancer Res 17:63CrossRefPubMedPubMedCentral

24.

Katalinic A, Eisemann N, Kraywinkel K et al (2019) Breast cancer incidence and mortality before and after implementation of the German mammography screening program. Int J Cancer. https://doi.org/10.1002/ijc.32767 CrossRefPubMed

25.

Jacklyn G, McGeechan K, Irwig L et al (2017) Trends in stage-specific breast cancer incidence in New South Wales, Australia: insights into the effects of 25 years of screening mammography. Breast Cancer Res Treat 166(3):843–854CrossRefPubMed

26.

Wu WY, Tornberg S, Elfstrom KM et al (2018) Overdiagnosis in the population-based organized breast cancer screening program estimated by a non-homogeneous multi-state model: a cohort study using individual data with long-term follow-up. Breast Cancer Res 20(1):153CrossRefPubMedPubMedCentral

27.

Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288(3):321–333CrossRefPubMed

28.

Ravdin PM, Cronin KA, Howlader N et al (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356(16):1670–1674CrossRefPubMed

29.

Anderson WF, Reiner AS, Matsuno RK, Pfeiffer RM (2007) Shifting breast cancer trends in the United States. J Clin Oncol 25(25):3923–3929CrossRefPubMed

30.

Colditz GA, Bohlke K (2014) Priorities for the primary prevention of breast cancer. CA Cancer J Clin 64(3):186–194CrossRefPubMed

31.

Collaborative Group on Hormonal Factors in Breast Cancer (2019) Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 394(10204):1159–1168CrossRefPubMedCentral

32.

Poli A, Marangoni F, Visioli F (2012) Alcohol consumption and breast cancer risk. JAMA 307(7):666; author reply 666.CrossRefPubMed

33.

Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ et al (2017) Obesity and adverse breast cancer risk and outcome: mechanistic insights and strategies for intervention. CA Cancer J Clin 67(5):378–397CrossRefPubMedPubMedCentral

34.

Lee IM, Shiroma EJ, Lobelo F et al (2012) Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet 380(9838):219–229CrossRefPubMedPubMedCentral

35.

Beaber EF, Buist DS, Barlow WE et al (2014) Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age. Cancer Res 74(15):4078–4089CrossRefPubMedPubMedCentral

36.

Fisher B, Costantino JP, Wickerham DL et al (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97(22):1652–1662CrossRefPubMed

37.

Goss PE, Ingle JN, Ales-Martinez JE et al (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364(25):2381–2391CrossRefPubMed

38.

Tamimi RM, Spiegelman D, Smith-Warner SA et al (2016) Population attributable risk of modifiable and nonmodifiable breast cancer risk factors in postmenopausal breast cancer. Am J Epidemiol 184(12):884–893CrossRefPubMedPubMedCentral

39.

Smith BD, Smith GL, Hurria A et al (2009) Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 27(17):2758–2765CrossRefPubMed

40.

Manthey J, Shield KD, Rylett M et al (2019) Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study. Lancet 393(10190):2493–2502CrossRefPubMed

41.

Fentiman IS, Fourquet A, Hortobagyi GN (2006) Male breast cancer. The Lancet 367(9510):595–604CrossRef

42.

Kreiter E, Richardson A, Potter J, Yasui Y (2014) Breast cancer: trends in international incidence in men and women. Br J Cancer 110(7):1891–1897CrossRefPubMedPubMedCentral

43.

Talibov M, Hansen J, Heikkinen S et al (2019) Occupational exposures and male breast cancer: A nested case-control study in the Nordic countries. Breast 48:65–72CrossRefPubMed

44.

Ruddy KJ, Winer EP (2013) Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol 24(6):1434–1443CrossRefPubMed

Titel: Trends of female and male breast cancer incidence at the global, regional, and national levels, 1990–2017
verfasst von: Zhilin Chen
Lu Xu
Wenjie Shi
Fanyu Zeng
Rui Zhuo
Xinbao Hao
Pingming Fan
Publikationsdatum: 13.02.2020
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2020
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05561-1

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Trends of female and male breast cancer incidence at the global, regional, and national levels, 1990–2017

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1)

Accelerated aging in breast cancer survivors and its association with mortality and cancer recurrence

CYP24A1 polymorphisms and breast cancer risk

Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers

The role of Micro-CT in imaging breast cancer specimens

Management of brain metastases in breast cancer: a review of current practices and emerging treatments

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie